Research Roundup: ACT Accelerator funding pledges, low-cost tests for LMICs, and early antibody cocktail trial results

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign-up now to receive our weekly R&D News Roundup email. Moderna announced last week that it would “not enforce” its COVID-19–related patents against other vaccine makers and would be willing to license intellectual property for COVID-19 vaccines for the post-pandemic period. The company, which is currently developing one of the four front-running COVID-19 vaccine candidates, said in a statement that it feels a “special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible.” Some advocates have responded with praise for Moderna being the only company working on a drug or vaccine to pledge open-sharing of its COVID-19 patents, while other advocates question the motivations behind the pledge, given Moderna’s pending intellectual property legal challenges as well as recent consumer and political pressures for access. Moderna plans to submit its vaccine candidate for US Food and Drug Administration (FDA) emergency use authorization by November 25 and later as a candidate for the general population by late January 2021, with the aim of having it available for widespread distribution by spring 2021.BioNTech and Pfizer have begun a rolling submission of their COVID-19 vaccine candidate for review by the European Medicines Agency (EMA), a process that AstraZeneca’s vaccine candidate also began the previous week. The candidate, BNT162b2, was accepted for rolling review based on its strong preclinical and early clinical data, which showed antibody and T-cell responses in people dosed in early-phase trials. BioNTech and Pfizer subsequently launched a phase 3 clinical trial—so far enrolling 37,000 participants across several countries. EMA will start assessing data on the experimental candidate before all necessary evidence is available, allowing it to reduce time spent on a decision once pivotal clinical trial results are available.A monoclonal antibody treatment developed by Eli Lilly appears to be effective in reducing virus levels and preventing hospital use in COVID-19 patients. The treatment, a combination of two monoclonal antibodies, was tested in non-hospitalized patients sick with COVID-19. Eli Lilly is also developing and had previously released results for a similar treatment using a single antibody, for which the company has filed for FDA emergency use authorization. Both antibody regimens have been well-tolerated, with no serious side effects, according to a company statement. Eli Lilly has said it expects to file for emergency use authorization for its combination therapy next month and anticipates having 1 million single-antibody treatment doses and 50,000 combination treatment doses available in the fourth quarter of 2020.

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign-up now to receive our weekly R&D News Roundup email. Johnson & Johnson (J&J) has moved into phase 3 trials for its COVID-19 vaccine candidate, making the company the fourth vaccine maker to enter late-stage trials in the United States and the first to do so with a single-dose vaccine candidate. In addition to being single-dose, J&J’s vaccine candidate can be stored at refrigerator temperatures for three months, making it more accessible to countries with less health care infrastructure than vaccines that require freezing. The phase 3 trial will be run at sites in the United States, Brazil, Mexico, South Africa, and other countries, and will include significant representation of people over the age of 60 and minorities at disproportionate risk of infection, according to J&J. The company is enrolling up to 60,000 volunteers and has said the trial could yield results by the end of the year, allowing it to seek emergency use authorization in early 2021.The US Food and Drug Administration (FDA) recently authorized for emergency use the first COVID-19 antibody test designed for use at point of care, instead of requiring samples to be shipped and tested at a laboratory. The fingerstick blood test—manufactured by Assure Tech, represented by Azure Biotech in the United States—provides results for two types of coronavirus antibodies within 15 minutes, using a lined strip similar to a pregnancy test. During an independent evaluation run in June, the test was found to have no false-negative results and a 1.2 percent false-positive rate. FDA Commissioner Stephen Hahn emphasized in a statement that point-of-care tests are more convenient, require less resources, and will decrease the time spent running antibody tests, in comparison with tests requiring lab processing.Achieving equitable distribution of a COVID-19 vaccine, once available, will require overcoming substantial financing and misinformation hurdles, according to global health and development leaders who spoke at the United Nations General Assembly. While optimistic that a vaccine will be developed and can end the COVID-19 pandemic, leaders noted the importance of ensuring delivery to all in need, including communities at highest risk. One global mechanism working to ensure such equitable distribution is the COVID-19 Vaccine Global Access (COVAX) Facility, which intends to help ensure a vaccine reaches vulnerable populations by guaranteeing all participating low- and middle-income countries receive enough vaccines to cover 20 percent of their population. The COVAX Facility also includes 64 high-income countries and is working to raise US$2 billion to help produce 1 billion vaccine doses by the end of 2021.